Ibrance-Faslodex Combo Improves Survival of Advanced Breast Cancer Patients, Phase 3 Trial Shows
News
Adding Pfizer’s Ibrance (palbociclib) to standard treatment Faslodex (fulvestrant) significantly extended the survival of advanced breast cancer patients in a Phase 3 clinical trial, researchers report. Called PALOMA-3, the trial (NCT01942135) specifically ... Read more